The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
FDA: Amivantamab with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. EMA: Amivantamab in combination with carboplatin and pemetrexed for the first line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutationsPAPILLON
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+ exon 20 insertion mutations
PAPILLON
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Mirvetuximab soravtansine
-
Paclitaxel, pegylated liposomal doxorubicin, or topotecan. (Investigator’s choice of chemotherapy)
Mirvetuximab soravtansine-gynx for adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimensMIRASOL, Study 0416
Gynaecological Malignancies
Epithelial ovarian, fallopian tube or primary peritoneal cancer
FRalpha positive
MIRASOL, Study 0416
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Enzalutamide
-
Placebo + Leuprolide
As monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy EMBARK
Genitourinary Cancers
Prostate cancer
PSA doubling time ≤ 9 month
EMBARK
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Trastuzumab deruxtecan
-
Single arm
Trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment optionsDESTINY-Lung01
Thoracic Malignancies
Non-small-cell Lung Cancer
HER2 (IHC 3+)
DESTINY-Lung01
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Trastuzumab deruxtecan
-
Single arm
Trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment optionsDESTINY-PanTumor02
Tumor agnostic
-
HER2 (IHC 3+)
DESTINY-PanTumor02
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Alectinib
-
Platinum-Based ChT
Alectinib for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancerALINA
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK positive
ALINA
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
FINAL SCORE
F1
A
Nogapendekin alfa inbakicept
Bacillus Calmette-Guérin (BCG)
Single arm
Nogapendekin alfa inbakicept-pmln with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (Ta/T1; Cohort A)QUILT-3.032
Genitourinary Cancers
Urothelial Carcinoma (NMIBC)
BCG-unresponsive
QUILT-3.032
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Talazoparib
Enzalutamide
Placebo plus enzalutamide
Talazoparib with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).TALAPRO-2
Genitourinary Cancers
Prostate cancer
HRR gene-mutated
TALAPRO-2
3
PRELIMINARY SCORE
rPFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Repotrectinib
-
Single arm
Repotrectinib used for locally advanced or metastatic ROS1-positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive NSCLC who are TKI naïve.TRIDENT-1
Thoracic Malignancies
Non-small-cell Lung Cancer
ROS1-positive (TKI naïve)
TRIDENT-1
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Sugemalimab
Platinum-based chemotherapy
Placebo
Sugemalimab for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapyGEMSTONE-302
Thoracic Malignancies
Non-small-cell Lung Cancer
-
GEMSTONE-302
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Tarlatamab
-
Single arm
Tarlatamab treatment for the extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy (10mg)DeLLphi-301
Thoracic Malignancies
Small-cell Lung Cancer
-
DeLLphi-301
2
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
2
Repotrectinib
-
Single arm
Repotrectinib used for locally advanced or metastatic ROS1-positive non-small cell lung cancer. FDA approval that includes patients with ROS1-positive NSCLC who have previously received a ROS1 tyrosine kinase inhibitor (TKI)TRIDENT-1
Thoracic Malignancies
Non-small-cell Lung Cancer
ROS1-positive (previously received TKI)
TRIDENT-1
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Atezolizumab
-
Single arm
For adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS).Study ML39345
Sarcoma
Alveolar soft part
-
Study ML39345
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Melphalan
-
Single arm
A liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiationFOCUS
Skin Cancers
Uveal melanoma
-
FOCUS
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Adagrasib
Cetuximab
Single arm
Adagrasib plus cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine, oxaliplatin and irinotecan-based ChTKRYSTAL-1
Gastrointestinal Cancers
Colorectal Cancer
KRAS G12C-mutated
KRYSTAL-1
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Tislelizumab
Carboplatin and paclitaxel/carboplatin (Arm A)
Placebo + Chemoradiotherapy (Paclitaxel + Carboplatin) (Arm C)
Tislelizumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adult patients with squamous NSCLC who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLCRATIONALE 307
Thoracic Malignancies
Non-small-cell Lung Cancer - Squamous cell
-
RATIONALE 307
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Tislelizumab
Carboplatin and nab-paclitaxel/carboplatin (Arm B)
Placebo + Chemoradiotherapy (Paclitaxel + Carboplatin) (Arm C)
Tislelizumab in combination with carboplatin and nab-paclitaxel is indicated for the first-line treatment of adult patients with squamous NSCLC who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC.RATIONALE 307
Thoracic Malignancies
Non-small-cell Lung Cancer - Squamous cell
-
RATIONALE 307
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Durvalumab
Carboplatin, paclitaxel plus Olaparib
Carboplatin, paclitaxel, and placebo (arm A)
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR)DUO-E
Gynaecological Malignancies
Endometrial Cancer
-
DUO-E
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Durvalumab
Carboplatin and paclitaxel
Carboplatin, paclitaxel, and placebo (arm A)
FDA: Durvalumab is indicated with carboplatin plus paclitaxel followed by single-agent durvalumab for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). EMA: Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)DUO-E
Gynaecological Malignancies
Endometrial Cancer
-
DUO-E
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Pembrolizumab
Carboplatin and paclitaxel
Carboplatin, paclitaxel, and placebo
Pembrolizumab with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma. (Cohort data with dMMR)KEYNOTE-868/NRG-GY018
Gynaecological Malignancies
Endometrial Cancer
dMMR
KEYNOTE-868/NRG-GY018
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Pembrolizumab
Carboplatin and paclitaxel
Carboplatin, paclitaxel, and placebo
Pembrolizumab with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma. (Cohort data with pMMR)KEYNOTE-868/NRG-GY018
Gynaecological Malignancies
Endometrial Cancer
-
KEYNOTE-868/NRG-GY018
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Toripalimab
Paclitaxel + cisplatin
Placebo + paclitaxel + cisplatin
Toripalimab, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.JUPITER-06
Gastrointestinal Cancers
Esophageal Squamous Cell Carcinoma
-
JUPITER-06
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Zolbetuximab
Fluoropyrimidine and platinum containing ChT
Placebo plus CAPOX
Zolbetuximab, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2‑negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive.GLOW
Gastrointestinal Cancers
Gastric or gastroesophageal junction adenocarcinoma
HER2 negative, CLDN18.2 positive
GLOW
2
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
2
Amivantamab
Carboplatin and Pemetrexed
Carboplatin and Pemetrexed
Amivantamab in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).MARIPOSA-2
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR Exon 19 deletions or Exon 21 L858R substitution mutations
MARIPOSA-2
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Atezolizumab
-
Vinorelbine or gemcitabine (by investigator choice )
Atezolizumab as monotherapy is indicated for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapyIPSOS
Thoracic Malignancies
Non-small-cell Lung Cancer
-
IPSOS
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pembrolizumab
Chemoradiotherapy (Cisplatin)
Placebo + Chemoradiotherapy (Cisplatin)
FDA: Pembrolizumab with chemoradiotherapy for patients with FIGO 2014 Stage III-IVA cervical cancer. EMA: Pembrolizumab, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is indicated for the treatment of FIGO 2014 Stage III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy.ENGOT-cx11/GOG-3047/KEYNOTE-A18
Gynaecological Malignancies
Cervical Cancer
-
ENGOT-cx11/GOG-3047/KEYNOTE-A18
A
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F1
A
TTFields (NovoTTF-100A)
Temozolomide
Temozolomide
The medical device, the NovoTTF-100A indicated for use in combination with adjuvant temozolomide as a treatment for patients with newly diagnosed GBM following surgery, chemotherapy, and radiation therapyEF-14
Brain Tumours
Glioblastoma
-
EF-14
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Trastuzumab
-
Chemotherapy
Patients with HER2-positive early breast cancer following surgery, ChT (neoadjuvant or adjuvant) and RT (if applicable)HERA
As a single agent for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapyEMILIA
Breast Cancer
Breast Cancer
HER2+
EMILIA
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.